{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:15:12Z","timestamp":1761581712848,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T00:00:00Z","timestamp":1530316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/01809-9"],"award-info":[{"award-number":["2017\/01809-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00705-018-3920-9","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T02:11:08Z","timestamp":1530324668000},"page":"2757-2764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3\/NS4A protease inhibitors in S\u00e3o Paulo state"],"prefix":"10.1007","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-8776","authenticated-orcid":false,"given":"Regina C\u00e9lia","family":"Moreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"de Torres Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaspar","family":"Lisboa-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C\u00e1ssia Jacintho","family":"Mendes-Corr\u00eaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcilio Figueiredo","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Mello","family":"Malta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fabia Anita Ferraz","family":"Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg\u00f3rio Tadeu Fernando","family":"Dastoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Fusco Duarte","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Renato Rebello","family":"Pinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,30]]},"reference":[{"key":"3920_CR1","unstructured":"Global Hepatitis Report 2017 (2017) Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO"},{"key":"3920_CR2","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s11538-016-0170-4","volume":"78","author":"M Amaku","year":"2016","unstructured":"Amaku M, Burattini MN, Coutinho FAB et al (2016) Estimating the size of the HCV infection prevalence: a modeling approach using the incidence of cases reported to an official notification system. Bull Math Biol 78:970\u2013990","journal-title":"Bull Math Biol"},{"issue":"1","key":"3920_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0034-1371007","volume":"34","author":"JM Pawlotsky","year":"2014","unstructured":"Pawlotsky JM (2014) New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis 34(1):22\u201329","journal-title":"Semin Liver Dis"},{"key":"3920_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"Pawlotsky JM, Hepatitis C (2016) Virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151:70\u201386","journal-title":"Gastroenterology"},{"key":"3920_CR5","unstructured":"AASLD (2016) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus [Internet]. [cited 2016 Nov 5]. \n                    http:\/\/www.hcvguidelines.org\/full-report-view"},{"key":"3920_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/S0074-02762013000100002","volume":"108","author":"LB Zeminian","year":"2013","unstructured":"Zeminian LB, Padovani JL, Corvino SM, Silva GF (2013) Pardini MIDMC, Grotto RMT. Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors. Mem Inst Oswaldo Cruz 108:13\u201317","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"3920_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C (2016) The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486\u2013504","journal-title":"J Hepatol"},{"key":"3920_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3851\/IMP2873","volume":"20","author":"G Lisboa-Neto","year":"2015","unstructured":"Lisboa-Neto G, Noble CF, Rebello Pinho JR et al (2015) Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection. Antivir Ther 20:281\u2013287","journal-title":"Antivir Ther"},{"key":"3920_CR9","doi-asserted-by":"crossref","unstructured":"Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463\u20135467","DOI":"10.1073\/pnas.74.12.5463"},{"key":"3920_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","volume":"99","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Sulkowski M, Jacobson I, Kraft WK et al (2013) Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. Antivir Res 99:214\u2013220","journal-title":"Antivir Res"},{"key":"3920_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1358\/dot.2015.51.11.2414528","volume":"51","author":"JD Zeuli","year":"2015","unstructured":"Zeuli JD, Adie SK, Rizza SA, Temesgen Z (2015) Asunaprevir plus daclatasvir for the treatment of chronic hepatitis virus infection. Drugs Today 51:629\u2013643","journal-title":"Drugs Today"},{"key":"3920_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","volume":"108","author":"E Poveda","year":"2014","unstructured":"Poveda E, Wyles DL, Mena A, Pedreira JD (2014) Update on hepatitis C virus resistance to direct-acting antiviral agentes. Antivir Res 108:181\u2013191","journal-title":"Antivir Res"},{"key":"3920_CR13","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1128\/AAC.01953-15","volume":"59","author":"SB Jansen","year":"2015","unstructured":"Jansen SB, Serre SBN, Humes DG et al (2015) Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance. Antimicrob Agents Chemother 59:7426\u20137436","journal-title":"Antimicrob Agents Chemother"},{"key":"3920_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jvh.12503","volume":"23","author":"LL Vidal","year":"2016","unstructured":"Vidal LL, Soares MA, Santos AF (2016) NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-na\u0131ve subjects. J Viral Hepatitis 23:840\u2013849","journal-title":"J Viral Hepatitis"},{"key":"3920_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","volume":"444","author":"RJ Bernard","year":"2013","unstructured":"Bernard RJ, Howe JA, Orget RA et al (2013) Analysis of Boceprevir resistence associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 444:329\u2013336","journal-title":"Virology"},{"key":"3920_CR16","doi-asserted-by":"publisher","first-page":"e39652","DOI":"10.1371\/journal.pone.0039652","volume":"7","author":"V Cento","year":"2012","unstructured":"Cento V, Mirabelli C, Salpini R et al (2012) HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 7:e39652","journal-title":"PLoS One"},{"key":"3920_CR17","doi-asserted-by":"publisher","first-page":"e86413","DOI":"10.1371\/journal.pone.0086413","volume":"9","author":"AS Nishiya","year":"2014","unstructured":"Nishiya AS, De Almeida-Neto C, Ferreira SC et al (2014) HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in Sao Paulo, Brazil. PLoS One. 9:e86413","journal-title":"PLoS One."},{"key":"3920_CR18","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica (2016) IBGE\u2014Estado de S\u00e3o Paulo [Internet]. [cited 2017 Apr 22]. \n                    http:\/\/www.ibge.gov.br\/estadosat\/perfil.php?sigla=sp"},{"key":"3920_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bjid.2015.06.010","volume":"19","author":"AS Nishiya","year":"2015","unstructured":"Nishiya AS, de Almeida-Neto C, Romano CM et al (2015) Phylogenetic analysis of the emergence of main hepatitis C virus subtypes in S\u00e3o Paulo, Brazil, Brazilian. Braz J Infect Dis 19:473\u2013478","journal-title":"Braz J Infect Dis"},{"key":"3920_CR20","doi-asserted-by":"publisher","first-page":"e1000198","DOI":"10.1371\/journal.pmed.1000198","volume":"6","author":"G Magiorkinis","year":"2009","unstructured":"Magiorkinis G, Magiorkinis E, Paraskevis D et al (2009) The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med 6:e1000198","journal-title":"PLoS Med"},{"key":"3920_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1590\/S1415-790X1998000200009","volume":"1","author":"WT Caiaffa","year":"1998","unstructured":"Caiaffa WT, Bastos FI (1998) Usu\u00e1rios de drogas injet\u00e1veis e infec\u00e7\u00e3o pelo V\u00edrus da Imunodefici\u00eancia Humana: epidemiologia e perspectivas de interven\u00e7\u00e3o. Rev Bras Epidemiol 1:190\u2013202","journal-title":"Rev Bras Epidemiol"},{"key":"3920_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3851\/IMP2606","volume":"18","author":"E Lampe","year":"2013","unstructured":"Lampe E, Lewis-Ximenez L, Esp\u00edrito-Santo MP et al (2013) Genetic diversity of HCV in Brazil. Antivir Ther 18:435\u2013444","journal-title":"Antivir Ther"},{"key":"3920_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","volume":"11","author":"JY Chen","year":"2014","unstructured":"Chen JY, Feeney ER, Chung RT (2014) HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol 11:362\u2013371","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3920_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/hep.28467","volume":"64","author":"P Kwo","year":"2016","unstructured":"Kwo P, Gitlin N, Nahass R et al (2016) Simeprevir plus sofosbuvir (12 and 8\u00a0weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 64:370\u2013380","journal-title":"Hepatology"},{"key":"3920_CR25","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/hep.29130","volume":"65","author":"E Lawitz","year":"2017","unstructured":"Lawitz E, Poordad F, Wells J et al (2017) Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV. Hepatology 65:1803\u20131809","journal-title":"Hepatology"},{"key":"3920_CR26","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","volume":"62","author":"O Lenz","year":"2015","unstructured":"Lenz O, Verbinnen T, Fevery B et al (2015) Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies. J Hepatol 62:1008\u201310014","journal-title":"J Hepatol"},{"key":"3920_CR27","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/infdis\/jiu613","volume":"211","author":"RM McCloskey","year":"2015","unstructured":"McCloskey RM, Liang RH, Joy JB et al (2015) Global origin and transmission of hepatitis C Virus nonstructural protein 3 Q80K polymorphism. J Infect Dis 211:1288\u20131295","journal-title":"J Infect Dis"},{"key":"3920_CR28","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/S0168-8278(16)01644-5","volume":"64","author":"S Susser","year":"2016","unstructured":"Susser S, Dietz J, Vermehren J et al (2016) European Ravs database: frequency and characteristics of Ravs in treatment-Na\u00efve and DAA-experienced patients. J Hepatol 64:S139","journal-title":"J Hepatol"},{"key":"3920_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3851\/IMP3057","volume":"21","author":"KV Gaspareto","year":"2016","unstructured":"Gaspareto KV, Ribeiro RM, de Malta F et al (2016) Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform. Antivir Ther 21:653\u2013660","journal-title":"Antivir Ther"},{"key":"3920_CR30","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.3390\/v7122941","volume":"7","author":"S Fourati","year":"2015","unstructured":"Fourati S, Pawlotsky JM (2015) Virologic tools for HCV drug resistance testing. Viruses 7:6346\u20136359","journal-title":"Viruses"},{"key":"3920_CR31","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/jmv.24527","volume":"88","author":"N Coppola","year":"2016","unstructured":"Coppola N, Minichini C, Starace M, Sagnelli C, Sagnelli E (2016) Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. J Med Virol 88:1659\u20131671","journal-title":"J Med Virol"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-018-3920-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-018-3920-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-018-3920-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T10:46:56Z","timestamp":1569149216000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-018-3920-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,30]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["3920"],"URL":"https:\/\/doi.org\/10.1007\/s00705-018-3920-9","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"type":"print","value":"0304-8608"},{"type":"electronic","value":"1432-8798"}],"subject":[],"published":{"date-parts":[[2018,6,30]]},"assertion":[{"value":"20 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jo\u00e3o Renato Rebello Pinho is an employee of Albert Einstein Medicina Diagn\u00f3stica, S\u00e3o Paulo, Brazil. All other authors who took part in this study declare that they have no conflicts of interest or disclosures with respect to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The procedures described in this study were only initiated after obtaining approval from the ethics committees of the participating institutions. This study was approved by the Ethical Committee in Research at the Instituto Adolfo Lutz (CEPIAL #1.040.338-2015).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}